Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts

Molecular Medicine Reports

Volumn 17, Issue 5, 2018, Pages 6887-6892

  Meng, Liping ^a,b   Uzui, Hiroyasu ^a   Guo, Hangyuan ^b   Tada, Hiroshi ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Cardiac Fibrosis; Glucose; Matrix Metalloproteinases; Phlorizin; Sodium Glucose Cotransporter 1

Indexed keywords

DAPAGLIFLOZIN; GELATINASE A; GELATINASE B; GLUCOSE; PHLORIZIN; SODIUM GLUCOSE COTRANSPORTER 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; SLC5A1 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; WESTERN BLOTTING; CARDIAC MUSCLE; CELL CULTURE; CYTOLOGY; DIABETIC CARDIOMYOPATHY; FIBROBLAST; FIBROSIS; GENETICS; HYPERGLYCEMIA; METABOLISM;

CELLS, CULTURED; DIABETIC CARDIOMYOPATHIES; FIBROBLASTS; FIBROSIS; GLUCOSE; HUMANS; HYPERGLYCEMIA; MATRIX METALLOPROTEINASE 2; MYOCARDIUM; SODIUM-GLUCOSE TRANSPORTER 1; TISSUE INHIBITOR OF METALLOPROTEINASE-1; UP-REGULATION;

EID: 85044776499     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2018.8688     Document Type: Article

References (32)

1. Fang ZY, Prins JB and Marwick TH: Diabetic cardiomyopathy: Evidence, mechanisms and therapeutic implications. Endocr Rev 25: 543-567, 2004.
2. DeCoux A, Lindsey ML, Villarreal F, Garcia RA and Schulz R: Myocardial matrix metalloproteinase-2: Inside out and upside down. J Mol Cell Cardiol 77: 64-72, 2014.
3. Li Q, Sun SZ, Wang Y, Tian YJ and Liu MH: The roles of MMP-2/TIMP-2 in extracellular matrix remodelling in the hearts of STZ-induced diabetic rats. Acta Cardiol 62: 485-491, 2007.
4. Chen SL, Hu ZY, Zuo GF, Li MH and Li B: I(f) current channel inhibitor (ivabradine) deserves cardioprotective effect via down-regulating the expression of matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic mice. BMC Cardiovasc Disord 14: 150, 2014.
5. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al: Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 373: 2117-2128, 2015.
6. Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J and Parikh SJ: Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care 38: 1218-1227, 2015.
7. Song P, Onishi A, Koepsell H and Vallon V: Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Exp Opin Ther Targets 20: 1109-1125, 2016.
8. Kashiwagi Y, Nagoshi T, Yoshino T, Tanaka TD, Ito K, Harada T, Takahashi H, Ikegami M, Anzawa R and Yoshimura M: Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice. PLoS One 10: E0130605, 2015.
9. Banerjee SK, Ramani R, Saba S, Rager J, Tian R, Mathier MA and Ahmad F: A PRKAG2 mutation causes biphasic changes in myocardial AMPK activity and does not protect against ischemia. Biochem Biophys Res Commun 360: 381-387, 2007.
10. Ramratnam M, Sharma RK, D'Auria S, Lee SJ, Wang D, Huang XY and Ahmad F: Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. J Am Heart Assoc 3: E000899, 2014.
11. Das S, Mandal M, Chakraborti T, Mandal A and Chakraborti S: Isolation of MMP-2 from MMP-2/TIMP-2 complex: Characterization of the complex and the free enzyme in pulmonary vascular smooth muscle plasma membrane. Biochim Biophys Acta 1674: 158-174, 2004.
12. Avolio C, Filippi M, Tortorella C, Rocca MA, Ruggieri M, Agosta F, Tomassini V, Pozzilli C, Stecchi S, Giaquinto P, et al: Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: Relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler 11: 441-446, 2005.
13. Liu X, Song X, Lu J, Chen X, Liang E, Liu X, Zhang M, Zhang Y, Du Z and Zhao Y: Neferine inhibits proliferation and collagen synthesis induced by high glucose in cardiac fibroblasts and reduces cardiac fibrosis in diabetic mice. Oncotarget 7: 61703-61715, 2016.
14. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW and Grishman A: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30: 595-602, 1972.
15. Jia G, Whaley-Connell A and Sowers JR: Diabetic cardiomyopathy: A hyperglycaemia-and insulin-resistance-induced heart disease. Diabetologia 61: 21-28, 2017.
16. Zou C, Liu X, Xie R, Bao Y, Jin Q, Jia X, Li L and Liu R: Deferiprone attenuates inflammation and myocardial fibrosis in diabetic cardiomyopathy rats. Biochem Biophys Res Commun 486: 930-936, 2017.
17. Lo SH, Hsu CT, Niu HS, Niu CS, Cheng JT and Chen ZC: Cryptotanshinone inhibits STAT3 signaling to alleviate cardiac fibrosis in type 1-like diabetic rats. Phytother Res 31: 638-646, 2017.
18. Wang XW, Zhang FX, Yang F, Ding ZF, Agarwal N, Guo ZK and Mehta JL: Effects of linagliptin and liraglutide on glucose-and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro. Acta Pharmacol Sin 37: 1349-1358, 2016.
19. Li J, Dai Y, Su Z and Wei G: MicroRNA-9 inhibits high glucose-induced proliferation, differentiation and collagen accumulation of cardiac fibroblasts by down-regulation of TGFBR2. Biosci Rep 36: E00417, 2016.
20. Meng L, Liu L, Zhou C, Pan S, Zhai X, Jiang C, Guo Y, Ji Z, Chi J, Peng F and Guo H: Polyphenols and polypeptides in chinese rice wine inhibit homocysteine-induced proliferation and migration of vascular smooth muscle cells. J Cardiovasc Pharmacol 67: 482-490, 2016.
21. Shi YF, Chi JF, Tang WL, Xu FK, Liu LB, Ji Z, Lv HT and Guo HY: Effects of rosuvastatin on the production and activation of matrix metalloproteinase-2 and migration of cultured rat vascular smooth muscle cells induced by homocysteine. J Zhejiang Univ Sci B 14: 696-704, 2013.
22. Siddesha JM, Valente AJ, Sakamuri SS, Yoshida T, Gardner JD, Somanna N, Takahashi C, Noda M and Chandrasekar B: Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. J Mol Cell Cardiol 65: 9-18, 2013.
23. Cauwe B and Opdenakker G: Intracellular substrate cleavage: A novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 45: 351-423, 2010.
24. Hughes BG, Fan X, Cho WJ and Schulz R: MMP-2 is localized to the mitochondria-associated membrane of the heart. Am J Physiol Heart Circ Physiol 306: H764-H770, 2014.
25. Westermann D, Savvatis K, Lindner D, Zietsch C, Becher PM, Hammer E, Heimesaat MM, Bereswill S, Volker U, Escher F, et al: Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy. Circulation 124: 2082-2093, 2011.
26. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM and Feder JN: Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 1: 57-92, 2010.
27. Jin X, Yi L, Chen ML, Chen CY, Chang H, Zhang T, Wang L, Zhu JD, Zhang QY and Mi MT: Delphinidin-3-glucoside protects against oxidized low-density lipoprotein-induced mitochondrial dysfunction in vascular endothelial cells via the sodium-dependent glucose transporter SGLT1. PLoS One 8: E68617, 2013.
28. Balteau M, Tajeddine N, de Meester C, Ginion A, Des Rosiers C, Brady NR, Sommereyns C, Horman S, Vanoverschelde JL, Gailly P, et al: NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc Res 92: 237-246, 2011.
29. Van Steenbergen A, Balteau M, Ginion A, Ferte L, Battault S, Ravenstein CM, Balligand JL, Daskalopoulos EP, Gilon P, Despa F, et al: Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. Sci Rep 7: 41166, 2017.
30. Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L, Luconi M and Mannucci E: Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. Int J Cardiol 243: 86-90, 2017.
31. Ye Y, Bajaj M, Yang HC, Perez-Polo JR and Birnbaum Y: SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther 31: 119-132, 2017.
32. Joubert M, Jagu B, Montaigne D, Marechal X, Tesse A, Ayer A, Dollet L, Le May C, Toumaniantz G, Manrique A, et al: The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes 66: 1030-1040, 2017.